Výsledky vyhledávání - "MESH : Paclitaxel"

Induction chemotherapy before surgery for unresectable head and neck cancer

Autor: Schmaltz H, Borel C, Ciftci S, Takeda-Raguin C, Debry C, Schultz P, Agnès Dupret-Bories

Publikováno v: B-ENT
B-ENT, 2021, 12 (1), pp.29-32
ResearcherID
Europe PubMed Central

To preoperatively reduce tumour size in patients with locally advanced and/or non-resectable squamous cell carcinoma with induction chemotherapy in order to achieve surgical excision with clear margins and preserve quality of life.In this study, 16 p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b8d339d7f4d1efffb3bc64236ad5fa7c
https://hal.archives-ouvertes.fr/hal-03439029

Zobrazit plný text záznamu

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Publikováno v: The Lancet
The Lancet, Elsevier, 2020, 396 (10257), pp.1090-1100. ⟨10.1016/S0140-6736(20)31953-X⟩

Summary Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo comb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e52d5af8d01ad9b7f0473fadec775
https://hal.archives-ouvertes.fr/hal-03046446

Zobrazit plný text záznamu

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial

Autor: C. de la Fouchardière, Marc Ychou, Françoise Desseigne, F. Portales, Caroline Mollevi, S. Iltache, Thibault Mazard, C. Fiess, Antoine Debourdeau, Eric Assenat

Publikováno v: ESMO Open
ESMO Open, 2021, 6 (6), pp.100318. ⟨10.1016/j.esmoop.2021.100318⟩

Background Nab-paclitaxel/gemcitabine (AG) and FOLFIRINOX (FFX) are promising drugs in metastatic pancreatic cancer (MPC). This study evaluated a new first-line sequential treatment (AG followed by FFX) in MPC that might overcome resistance to primar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05b7f8bb2415f9c13a7733d1658283d9
https://doi.org/10.1016/j.esmoop.2021.100318

Zobrazit plný text záznamu

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study

Autor: Philippe Ardisson, Jean-Paul Guastalla, Pierre Meeus, Agathe Bajard, Armelle Dufresne, Isabelle Moullet, Lionel Vincent, Isabelle Ray-Coquard, Intidhar Labidi Galy, Jean-Emmanuel Kurtz, David Coeffic, Irène Asmane, Olivier Tredan, Jean-Pierre Bergerat

Publikováno v: Bulletin du Cancer
Bulletin du Cancer, 2011, 98 (9), pp.80-9. ⟨10.1684/bdc.2011.1436⟩
Bulletin du Cancer, John Libbey Eurotext, 2011, 98 (9), pp.80-9. ⟨10.1684/bdc.2011.1436⟩

International audience; OBJECTIVES. As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7207bfb7eac6e9583615dc9cbac738f7
https://doi.org/10.1684/bdc.2011.1436

Zobrazit plný text záznamu

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

Publikováno v: PLoS ONE
PLoS ONE, 2016, 11 (7), pp.e0154009. ⟨10.1371/journal.pone.0154009⟩
PloS one, 11 (7
PLoS ONE, Vol 11, Iss 7, p e0154009 (2016)
PLoS ONE, Public Library of Science, 2016, 11 (7), pp.e0154009. ⟨10.1371/journal.pone.0154009⟩

Background: EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) in combination with paclitaxel. Methods: HER2-negative BC patients candidates for neoadjuvant chemotherapy were scheduled t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d82bd990c0f337145afa70c619fe01
https://hal.umontpellier.fr/hal-02296718

Zobrazit plný text záznamu

Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma

Autor: Désiré Challuau, Benoît Hosten, Michel Perricaudet, Céline Bouquet, Sylvie Marion, Sophie Gil, Robert Farinotti, Mario Di Palma, Laurence Bonhomme-Faivre

Publikováno v: Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2006, 17 (2), pp.195-9

International audience; The aim of the present study was to examine modifications of anti-tumor activity and toxicity of paclitaxel (PLX) when given p.o. after recombinant interleukin-2 (rIL-2) to Lewis lung carcinoma-bearing mice. PLX was given oral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce51685c97b1105e926891843995a73
https://doi.org/10.1097/00001813-200602000-00011

Zobrazit plný text záznamu

Glycoprotein 170 Induces Platelet-Activating Factor Receptor Membrane Expression and Confers Tumor Cell Hypersensitivity to NK-Dependent Cell Lysis

Autor: Christina Fleet, Yves Denizot, Jean-François Bourge, Philippe Leboulch, Rob Pawliuk, François Sigaux, Christian Berthou, Eugene Michel, Daniela Geromin, Annie Soulié, Marilyne Sasportes

Publikováno v: Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2004, 172 (6), pp.3604-11

Multidrug resistance (MDR) confers resistance to anticancer drugs and reduces therapeutic efficiency. It is often characterized by the expression of the MDR1 gene product P-glycoprotein (or gp170) at the membrane of tumor cells. To further propose a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270b879b3df53cb7f8ed1eb895e01a5e
https://doi.org/10.4049/jimmunol.172.6.3604

Zobrazit plný text záznamu

Bcl-2 Phosphorylation and Proteasome-Dependent Degradation Induced by Paclitaxel Treatment: Consequences on Sensitivity of Isolated Mitochondria to Bid

Autor: Nadia Barboule, Annie Valette, L. Brichese, C. Heliez

Publikováno v: Experimental Cell Research
Experimental Cell Research, Elsevier, 2002, 278 (1), pp.101-11

Several studies have suggested that Bcl-2 phosphorylation, which occurs during mitotic arrest induced by paclitaxel, inhibits its antiapoptotic function. In the present study, we demonstrated that the level of phosphorylated Bcl-2 was threefold highe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd20f9221702ed92e528a961bc669b26
https://doi.org/10.1006/excr.2002.5563

Zobrazit plný text záznamu

Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer

Autor: Jean-Pierre Kantelip, Xavier Pivot, Bruno Chauffert, Emmanuel Guardiola, Delphine Delroeux, Marielle Combe, Bernard Royer, Guillaume Hoizey, Bruno Heyd, Damien Montange

Publikováno v: Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2008, 61 (3), pp.415-21. 〈10.1007/s00280-007-0484-x〉
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2008, 61 (3), pp.415-21. ⟨10.1007/s00280-007-0484-x⟩

International audience; Ovarian cancer is the leading cause of gynecological cancer-related death in Western countries. The present treatment standards for ovarian cancer are based on the association of debulking surgery with platinum-based chemother

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f45ee03c163a7d726dcb6cf62024e50
http://www.hal.inserm.fr/inserm-00483417

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání